Literature DB >> 25610591

The first annual Drug Discovery and Development Symposium for Pulmonary Hypertension.

John H Newman1.   

Abstract

Entities:  

Year:  2014        PMID： 25610591      PMCID： PMC4278615          DOI： 10.1086/679063

Source DB:  PubMed          Journal:  Pulm Circ        ISSN： 2045-8932            Impact factor:   3.017


× No keyword cloud information.
  7 in total

1.  Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.

Authors:  Lahouaria Hadri; Razmig G Kratlian; Ludovic Benard; Bradley A Maron; Peter Dorfmüller; Dennis Ladage; Christophe Guignabert; Kiyotake Ishikawa; Jaume Aguero; Borja Ibanez; Irene C Turnbull; Erik Kohlbrenner; Lifan Liang; Krisztina Zsebo; Marc Humbert; Jean-Sébastien Hulot; Yoshiaki Kawase; Roger J Hajjar; Jane A Leopold
Journal:  Circulation       Date:  2013-06-26       Impact factor: 29.690

Review 2.  The metabolic theory of pulmonary arterial hypertension.

Authors:  Roxane Paulin; Evangelos D Michelakis
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 3.  Targeting the Wnt signaling pathways in pulmonary arterial hypertension.

Authors:  Vinicio de Jesus Perez; Ke Yuan; Tero-Pekka Alastalo; Edda Spiekerkoetter; Marlene Rabinovitch
Journal:  Drug Discov Today       Date:  2014-06-20       Impact factor: 7.851

4.  Inflammation in pulmonary arterial hypertension: is it time to quell the fire?

Authors:  Paul M Hassoun
Journal:  Eur Respir J       Date:  2014-03       Impact factor: 16.671

Review 5.  Novel therapeutic approaches to preserve the right ventricle.

Authors:  Samar Farha; Erika L Lundgrin; Serpil C Erzurum
Journal:  Curr Heart Fail Rep       Date:  2013-03

6.  Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p.

Authors:  Salil Sharma; Soban Umar; Francois Potus; Andrea Iorga; Gabriel Wong; David Meriwether; Sandra Breuils-Bonnet; Denise Mai; Kaveh Navab; David Ross; Mohamad Navab; Steeve Provencher; Alan M Fogelman; Sébastien Bonnet; Srinivasa T Reddy; Mansoureh Eghbali
Journal:  Circulation       Date:  2014-06-24       Impact factor: 29.690

7.  Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.

Authors:  Lan Zhao; Chien-Nien Chen; Nabil Hajji; Eduardo Oliver; Emanuele Cotroneo; John Wharton; Daren Wang; Min Li; Timothy A McKinsey; Kurt R Stenmark; Martin R Wilkins
Journal:  Circulation       Date:  2012-06-18       Impact factor: 29.690
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.